Compare Davita Inc (DVA) vs Morgan Stanley (MS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Morgan Stanley — how do they compare? Davita Inc trades at $230.53 (market cap $14.92B), while Morgan Stanley trades at $232 (market cap $359.10B). The key difference: Morgan Stanley is far larger — about 24.1× Davita Inc's market cap, and Morgan Stanley pays a 1.76% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | MS | |
|---|---|---|
Market Cap | $14.92B | $359.10B |
Sector | Health | Financials |
52-Week High | $235.71 | $228.17 |
52-Week Low | $103.87 | $139.09 |
Enterprise Value | $27.47B | — |
Dividend Yield | — | 1.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
Morgan Stanley (MS) trades at $228.17, up 2.65% on the day, with strong bullish momentum from three consecutive quarterly earnings beats. The stock shows robust revenue growth, reaching $66.0B in 2025, and a net income margin of 25.56%. Technical indicators signal a bullish trend, with moving averages supporting upward movement, while RSI levels suggest mixed short-term momentum. Recent news highlights Morgan Stanley's role in leading Anthropic's IPO and expanding AI integration in wealth management, reinforcing its market position.
Outlook remains positive with analyst consensus favoring Buy ratings (53.85%) and a price target of $225.80, slightly below current levels. Key opportunities include continued earnings outperformance and strategic initiatives in AI and IPO leadership. Risks involve volatile cash flows, high debt levels, and macroeconomic sensitivity. Investors should weigh strong fundamentals against execution risks in a dynamic financial landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →
